Afobazole

Afobazole (INN fabomotizole; development code CM-346; CAS 173352-21-1) is a 2-mercaptobenzimidazole anxiolytic synthesized and pharmacologically characterized at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences under the direction of Academician S.B. Seredenin. The compound was registered in the Russian Federation in 2006 for the treatment of generalized anxiety disorder and adjustment disorders, and was assigned the International Nonproprietary Name fabomotizole by the World Health Organization in 2012. Structurally, afobazole is 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole, a synthetic benzimidazole bearing a thioether-linked morpholine side chain and an ethoxy substituent on the aromatic ring. The molecular formula is C15H21N3O2S (free base, molecular weight 307.41 g/mol), and the compound is supplied pharmaceutically as the dihydrochloride salt (C15H23Cl2N3O2S, molecular weight 380.33 g/mol).

The pharmacological profile of afobazole is multi-target. Radioligand binding studies have identified the sigma-1 receptor chaperone protein (Sigma1R; Ki approximately 5.9 micromolar), NRH:quinone reductase 2 (NQO2, also designated the MT3 melatonin binding site; Ki approximately 0.97 micromolar), monoamine oxidase A (MAO-A regulatory site; Ki approximately 3.6 micromolar), and the melatonin MT1 receptor (Ki approximately 16 micromolar) as the principal molecular targets [1, 2]. The sigma-1 receptor interaction is the best-characterized mechanism: afobazole acts as a Sigma1R agonist, promoting dissociation of the Sigma1R-BiP complex at the endoplasmic reticulum membrane and downstream modulation of calcium signaling, inositol 1,4,5-trisphosphate receptor function, and expression of neurotrophic factors including nerve growth factor and brain-derived neurotrophic factor [3, 4]. The anxiolytic effect is blocked by selective Sigma1R antagonists (BD-1047, NE-100) in rodent behavioral models, confirming the dependence of the therapeutic activity on Sigma1R engagement [5, 6]. Unlike benzodiazepines, afobazole does not produce sedation, myorelaxation, amnesia, tolerance, physical dependence, or withdrawal syndrome at therapeutic doses, a profile confirmed in both preclinical and clinical studies [7, 8].

Pharmacokinetics are characterized by rapid oral absorption (Tmax approximately 0.85 hours), pronounced first-pass hepatic metabolism (oral bioavailability approximately 44 percent), and a short plasma elimination half-life (approximately 0.82 hours) [9]. Despite the short systemic half-life, the anxiolytic effect persists substantially beyond the plasma residence of the parent compound, a pharmacodynamic feature attributed to the slow dissociation kinetics of the Sigma1R chaperone complex and to the sustained expression of downstream neurotrophic mediators. The recommended therapeutic dose is 30 mg per day in three divided administrations of 10 mg, with clinical effect emerging after 5 to 7 days of continuous dosing and maximal effect at 4 weeks [8, 10].

The clinical evidence base comprises several Russian multicenter trials. The principal registration study was a randomized, double-blind, active-controlled trial of 150 patients with generalized anxiety disorder or adjustment disorders comparing afobazole (30 mg/day) to diazepam (30 mg/day) for 30 days; afobazole produced greater reduction in Hamilton Anxiety Rating Scale total score than diazepam (mean difference 2.93 points; p = 0.01), with 15 adverse events in the afobazole group versus 199 in the diazepam group, and no withdrawal syndrome on discontinuation [8]. Additional studies have evaluated afobazole in somatoform disorders, irritable bowel syndrome, premenstrual syndrome, alcohol withdrawal, and tobacco cessation, with consistent evidence of anxiolytic efficacy and favorable tolerability [10, 11, 12].

Preclinical research has extended the pharmacological profile well beyond anxiolysis. Afobazole produces Sigma1R-dependent neuroprotection in rat models of ischemic stroke (middle cerebral artery occlusion), with reduced infarct volume and improved neurological outcomes when administered up to 24 hours post-occlusion [13, 14]. In the 6-hydroxydopamine mouse model of Parkinson’s disease, afobazole at 2.5 mg/kg intraperitoneally for 14 days restored striatal dopamine content, preserved tyrosine hydroxylase-positive neurons in the substantia nigra, and normalized motor coordination; these effects were abolished by the Sigma1R antagonist BD-1047 [15, 16]. Cardioprotective activity has been demonstrated in models of isoproterenol-induced myocardial injury, chronic heart failure, and alcoholic cardiomyopathy, with attenuation of pathological remodeling, preserved inotropic function, and reduced brain natriuretic peptide levels [17, 18, 19]. Angiogenic effects have also been reported [20].

This monograph reviews the chemistry, synthesis, and structural class of afobazole; the multi-target molecular pharmacology with emphasis on the Sigma1R chaperone mechanism; the comprehensive pharmacokinetic profile; the preclinical pharmacology across anxiolytic, neuroprotective, cardioprotective, and anti-inflammatory models; the clinical evidence base in anxiety and related disorders; sourcing and quality considerations; reconstitution and handling; stack interactions; adverse events and safety signal; and a comparative assessment of five non-benzodiazepine anxiolytic candidates (buspirone, hydroxyzine, pregabalin, etifoxine, selank) against afobazole on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by the United States Food and Drug Administration or the European Medicines Agency. It is registered in the Russian Federation and is available as an over-the-counter pharmaceutical product within that jurisdiction and as a research-grade preparation from international chemical suppliers.